Literature DB >> 9458824

Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans.

K T Jensen1, J Carstens, E B Pedersen.   

Abstract

The effect of a continuous infusion of human brain natriuretic peptide (BNP) was studied in 48 healthy men. The study was randomized, placebo controlled, and single blind. BNP was given in doses of 1, 2, or 4 pmol.kg-1.min-1 for 60 min, and peak values of BNP in plasma were 38, 85, and 199 pmol/l, giving increments in plasma as seen in heart or renal failure. BNP infusion increased the urinary flow rate and the excretion of sodium in a dose-dependent way. The maximal effects were +65 and +156%, respectively. GFR increased and RPF decreased, the latter in a dose-dependent manner. Blood pressure, heart rate, angiotensin II, and aldosterone were all unaffected by infusion of BNP, whereas a direct inhibition of renin secretion was seen. With the use of the lithium clearance technique, we concluded that the tubular site of action is in both the proximal and distal segments, and the major effect on sodium handling is in the distal parts of the nephron.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458824     DOI: 10.1152/ajprenal.1998.274.1.F63

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  18 in total

1.  B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?

Authors:  P Welsh; J J McMurray
Journal:  Diabetologia       Date:  2012-03-08       Impact factor: 10.122

Review 2.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Nesiritide: a review of its use in acute decompensated heart failure.

Authors:  Gillian M Keating; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Brain natriuretic peptide and optimal management of heart failure.

Authors:  Nan Li; Jian-An Wang
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

Review 5.  Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.

Authors:  Dhssraj Singh; Akanksha Thakur; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2015-06

Review 6.  Management strategies for stage-D patients with acute heart failure.

Authors:  David Feldman; Doron M Menachemi; William T Abraham; Randell K Wexler
Journal:  Clin Cardiol       Date:  2008-07       Impact factor: 2.882

Review 7.  B-type natriuretic peptide: beyond a diagnostic.

Authors:  Fernando L Martin; Horng H Chen; Alessandro Cataliotti; John C Burnett
Journal:  Heart Fail Clin       Date:  2008-10       Impact factor: 3.179

Review 8.  Potential Expanded Indications for Neprilysin Inhibitors.

Authors:  Elizabeth Riddell; Justin M Vader
Journal:  Curr Heart Fail Rep       Date:  2017-04

9.  Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

Authors:  Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.